Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size to Reach USD 28.13 Billion by 2033 | Growing at 16.8% CAGR Driven by Rising Metabolic Disease Burden

The Non Alcoholic Steatohepatitis Therapeutics and Diagnostics Market reached USD 8.26 billion in 2024 and is projected to reach USD 28.13 billion by 2033, growing at a CAGR of 16.8% during the forecast period 2025 to 2033. The market is expanding rapidly due to the rising global prevalence of obesity, type 2 diabetes, and metabolic syndrome, which are major risk factors for non alcoholic steatohepatitis.

Non alcoholic steatohepatitis is an advanced form of non alcoholic fatty liver disease characterized by liver inflammation and fibrosis, which can progress to cirrhosis and hepatocellular carcinoma if untreated. Growing awareness, improved screening programs, and advancements in non invasive diagnostic technologies such as imaging biomarkers and serum based tests are accelerating early detection rates. On the therapeutic side, increasing research and development investments, expanding clinical pipelines, and regulatory approvals for novel targeted therapies are significantly driving market growth.

North America dominates the market due to strong clinical research infrastructure and high disease prevalence, while Asia Pacific is emerging as a high growth region supported by rising healthcare spending and increasing diagnosis rates. The integration of precision medicine approaches and biomarker driven treatment strategies is expected to further strengthen long term market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/non-alcoholic-steatohepatitis-therapeutics-and-diagnostics-market?sai-v

The Non Alcoholic Steatohepatitis Therapeutics and Diagnostics Market refers to the global industry focused on the development and commercialization of drugs and diagnostic technologies used to detect, monitor, and treat non alcoholic steatohepatitis, a progressive form of fatty liver disease characterized by inflammation and liver damage.

Key Developments

✅ February 2026: In North America and Europe, Eli Lilly and Company reported positive Phase III clinical trial results for its NASH therapeutic candidate showing significant liver fibrosis improvement, and announced plans to file regulatory submissions in major markets and expand development partnerships.

✅ January 2026: In global hepatology markets, Intercept Pharmaceuticals strengthened its NASH therapeutics portfolio with updated clinical data on metabolic-targeted agents and outlined future registrational trial expansion into Asia Pacific and Latin America.

✅ December 2025: In the United States, Genfit progressed its diagnostic platform for non-invasive NASH detection using advanced biomarker panels, and outlined plans to pursue broader commercial adoption through payer engagement and integration with clinical decision support systems.

✅ November 2025: Across Europe and North America, Gilead Sciences expanded its investigational NASH pipeline with combination therapy approaches targeting inflammation and fibrosis pathways, and announced plans to initiate additional Phase II/III cohorts.

✅ October 2025: In global diagnostics markets, Siemens Healthineers launched enhanced imaging and biochemical assay solutions aimed at improving early NASH diagnosis and staging, with future initiatives focused on AI-assisted interpretation and workflow integration.

✅ September 2025: In Asia Pacific, Fujifilm Healthcare advanced its non-invasive liver assessment technologies designed to support NASH screening and monitoring, and outlined partnerships with regional healthcare systems to expand deployment and training.

Key Players
Allergan plc | Pfizer Inc. | Gilead Sciences Inc. | Genfit SA | Novartis AG | Intercept Pharmaceuticals Inc. | Zydus Lifesciences Ltd. | Novo Nordisk A/S | Raptor Pharmaceutical Corp. | Galmed Pharmaceuticals Ltd. | Others

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=non-alcoholic-steatohepatitis-therapeutics-and-diagnostics-market?sai-v
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Market Drivers

Increasing Global Prevalence of NASH and Metabolic Liver Diseases: Rising incidence of non alcoholic steatohepatitis (NASH), driven by obesity, type 2 diabetes, and metabolic syndrome, is significantly expanding the need for targeted diagnostics and therapeutics.

Growing Focus on Early Diagnosis and Disease Stratification: Early identification of liver inflammation and fibrosis through advanced biomarkers and imaging is improving patient management and enabling more timely therapeutic intervention.

Lack of Approved Standard Therapeutics: With limited currently approved drug treatments for NASH, there is strong clinical and commercial interest in innovative agents that can arrest or reverse disease progression, driving investment into therapeutic research and development.

Advancements in Precision Diagnostics: Development of non-invasive diagnostic tools, such as enhanced imaging, serum biomarker panels, and algorithm-based risk scores, is reducing reliance on liver biopsy and enabling broader screening and monitoring.

Integration of Digital Health and Real-World Data: Digital platforms that collect longitudinal liver health metrics enable better patient risk profiling, therapy optimization, and post-treatment monitoring.

Industry Developments

Launch of Next-Generation Diagnostic Assays: Companies are developing non-invasive biomarker tests, multi-omic panels, and AI-enhanced imaging interpretation tools that improve accuracy in detecting NASH and staging fibrosis.

Advancements in Imaging Technologies: Novel elastography, MRI-based techniques, and quantitative ultrasound platforms are being adopted to assess liver fat, inflammation, and fibrosis in outpatient and specialty clinic settings.

Expanding Therapeutic Pipelines With Novel Mechanisms: Biopharmaceutical firms are progressing candidates targeting metabolic pathways, inflammation, and fibrosis (such as FXR agonists, GLP-1 analogs, and anti-fibrotic agents) through late-stage clinical trials.

Strategic Collaborations in Clinical Research: Alliances between biotech innovators, academic research centers, and large pharma are accelerating clinical trial enrolment, endpoint validation, and global development programs.

Integration of Companion Diagnostic and Therapeutic Strategies: Efforts to pair diagnostic tools with targeted therapies support personalised disease management and improve chances of regulatory success.

Regional Insights

North America - Holds around 42 percent share: Strong clinical research infrastructure, high prevalence of NASH, leading diagnostic adoption, and substantial investment in therapeutic pipelines support regional dominance.

Europe - Holds around 27 percent share: Growing healthcare focus on liver disease screening, structured fibrosis assessment programs, and favourable reimbursement environments sustain market growth.

Asia Pacific - Holds around 23 percent share: Rapid increase in obesity and diabetes rates in China, India, and Southeast Asia, expanding diagnostic capabilities, and rising healthcare expenditure drive significant regional expansion.

Latin America - Holds around 5 percent share: Improving awareness of liver disease, expanding specialty care access, and increasing investment in diagnostics and treatment contribute to market uptake.

Middle East & Africa - Holds around 3 percent share: Emerging healthcare infrastructure, rising metabolic disease burden, and development of diagnostic and therapeutic services support early stage market growth.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/non-alcoholic-steatohepatitis-therapeutics-and-diagnostics-market?sai-v

Key Segments

By Therapeutics
Ocaliva represents a leading therapeutic option, widely used for the treatment of cholestatic and certain chronic liver diseases, supported by regulatory approvals and clinical adoption. Elafibranor is gaining attention as a dual PPAR agonist targeting metabolic and inflammatory pathways in liver disorders. Cenicriviroc has been explored for its anti inflammatory and anti fibrotic properties in progressive liver conditions. Selonsertib is investigated for its potential to reduce fibrosis by targeting apoptosis signal regulating kinase pathways. Other therapeutics include emerging small molecules and biologics under clinical development aimed at addressing unmet needs in chronic liver disease management.

By Diagnostics
Imaging techniques account for a significant share, including ultrasound, MRI, and elastography methods used for non invasive assessment of liver structure and fibrosis progression. Diagnostic tests such as blood based biomarker panels are widely utilized for early detection, disease monitoring, and risk stratification. Biopsy remains the gold standard in certain cases, providing histological confirmation and detailed evaluation of inflammation and fibrosis severity.

By Sales Channel
Hospital pharmacies dominate the segment due to the specialized nature of therapies and the need for physician supervision. Online channels are expanding steadily, driven by digital healthcare adoption and patient preference for convenience. Retail channels contribute through prescription fulfillment and improved accessibility in community settings.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.